Clinical trials: T-lymphocytes
Extensive Stage Small Cell Lung Cancer
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1…
- Trial name
- DeLLphi-307 (NCT06502977)
- Testing
- Tarlatamab
- Where
- 12 sites in China
- Volunteers
- 32 people
- Sponsor
- Amgen
Lymphoma, Small Intestine Cancer
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing.
- Trial name
- NCT00561418
- Testing
- vorinostat, Correlative studies
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Relapsed/Refractory Multiple Myeloma
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell…
- Trial name
- NCT03318861
- Testing
- KITE-585, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kite, A Gilead Company
Soft Tissue Sarcoma
LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)
ATLAS-IT-04 is a two part, single arm study designed to determine the safety and effectiveness of LTX-315 to induce T-cell infiltration prior to TIL expansion in patients with soft tissue sarcoma.
- Trial name
- NCT03725605
- Testing
- LTX-315 and TILs
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Lytix Biopharma AS
Cervical Cancer, Pancreatic Cancer
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the…
- Conditions
- Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma
- Trial name
- NCT01583686
- Testing
- Fludarabine, Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL), Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease…
- Conditions
- Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Post-transplant Lymphoproliferative Disorder
- Trial name
- CIVIC (NCT02763254)
- Testing
- baltaleucel-T
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cell Medica Ltd
Acute Lymphoblastic Leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
- Trial name
- NCT00560794
- Testing
- Blinatumomab (MT103)
- Where
- 6 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Amgen Research (Munich) GmbH
Breast Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma
- Trial name
- NCT02153905
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1 Infection
Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
Adult participants (18-64 years old) with HIV-1 Infection on ART with a CD4 T cell count ≥ 350 cells/mm3 and viral suppression for ≥ 24 months will be enrolled on this study.
- Trial name
- NCT03803605
- Testing
- VRC07-523LS, Vorinostat (VOR)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Allogeneic Stem Cell Transplant, Viral Infection
Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant
The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent viral infections that may happen after allogeneic stem cell transplant.
- Trial name
- NCT03883906
- Testing
- Viral Specific T-cells (VSTs)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma
- Trial name
- NCT03396952
- Testing
- Aspirin, Ipilimumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
Peripheral T-cell Lymphoma
Treatment of Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide ) for patients with Peripheral T-cell lymphoma.
- Trial name
- NCT01664975
- Testing
- GDPT regimen, CHOP regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Mingzhi Zhang
Neoplasms
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
This screening study is intended to determine preliminary eligibility of participants who may be potential candidates for GlaxoSmithKline's Adoptive T-cell therapy studies by screening for appropriate biomarkers.
- Trial name
- NCT05100316
- Testing
- Screening Platform
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Healthy
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
Peripheral blood progenitor cells (PBPC) have become the preferred source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and shorter time required for engraftment.
- Trial name
- NCT00075335
- Testing
- AMD3100 (Mozobil plerixafor)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Hepatitis B
Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus（HBV） vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal…
- Trial name
- NCT00869778
- Testing
- εPA-44
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
HIV-1 Infection
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
This phase II study was done in HIV-infected participants on antiretroviral therapy to evaluate the effects of isotretinoin (a drug that is approved for use in the treatment of severe acne) on the immune system.
- Trial name
- NCT01969058
- Testing
- Isotretinoin
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 76 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Hematologic Diseases
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
This is a study involving patients who are undergoing allogeneic peripheral blood stem cell transplantation. Both donors and recipients are being sought for this study.
- Trial name
- NCT00208949
- Testing
- G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Emory University
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-Malignant Hematologic Disorders
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the…
- Trial name
- NCT03615144
- Testing
- Melphalan, Thiotepa, Clofarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center